This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEI7R01L_L.jpg
The drug candidate is a potential new treatment for patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, Bayer said.
Bayer’s best-selling stroke prevention pill Xarelto, in which partner Johnson & Johnson (NYSE:JNJ) holds some rights, will lose patent protection around 2026.
